Longevity Protocol with Heart Disease

How Cardiovascular Disease Accelerates Aging

Cardiovascular disease is more than clogged arteries. Plaque builds over decades, driven by cholesterol-carrying particles, high blood pressure, smoking, diabetes and inflammation, and once it is established it raises the risk of heart attack, stroke and heart failure.

If you already have heart disease, or carry strong risk factors such as high ApoB, high blood pressure, diabetes or a family history of early heart disease, the payoff from each measure below is larger, because your starting risk is higher.

The encouraging part is that risk can be lowered at every stage, before or after a first event, and most of the levers below have randomized trial evidence behind them.

Exercise: The Non-Negotiable Foundation

Exercise has some of the strongest evidence of any habit. In a pooled analysis of US and European cohorts covering more than 100,000 deaths, people who met the minimum activity guideline had 31 percent lower mortality than inactive people, and the benefit leveled off at three to five times the minimum (39 percent lower).¹ Fitness matters on its own: in a meta-analysis of 33 studies, each one-MET gain in fitness (roughly 1 km/h faster running speed) was linked to 13 percent lower all-cause mortality and 15 percent fewer cardiovascular events.²

Aerobic exercise (150–300 min/week) is the base. In a meta-analysis of exercise trials, endurance training lowered systolic blood pressure by about 3.5 mm Hg overall and about 8 mm Hg in people with hypertension.³ If you already have coronary heart disease, start with a cardiac rehabilitation program: in a Cochrane review, exercise-based rehabilitation cut heart attacks by 28 percent and hospital admissions by 42 percent in the following 6 to 12 months, although it made little difference to cardiovascular death.⁴

Resistance training (2–3 times a week) — The American Heart Association supports prescribed, supervised resistance training for people with and without heart disease because it improves strength, function and quality of life.⁵ Its effect on blood pressure is modest (about 2 mm Hg systolic in trials).³ Use moderate loads with controlled movements, and avoid heavy breath-holding lifts if your blood pressure is not controlled.

Fitness (VO2 max) is the goal. Among 122,007 adults who had treadmill tests, the least fit quarter had five times the mortality of the fittest group, a gap comparable to or larger than that for smoking or coronary artery disease, and people with below-average fitness had 41 percent higher mortality than those just above average.⁶ Once your doctor clears you, intervals are an efficient way to push fitness up.

Lipid Management: What the Trials Support

Lower LDL cholesterol means fewer events, with no clear floor in the trials so far. Across 26 randomized statin trials, each 1 mmol/L (about 39 mg/dL) lower LDL cholesterol cut major vascular events by about 22 percent, including in people whose LDL was already below 2 mmol/L (77 mg/dL).⁷

ApoB counts the particles. Each LDL and triglyceride-rich particle carries one ApoB molecule. In a genetic study of 654,783 people, variants that lowered triglycerides and variants that lowered LDL cholesterol cut coronary risk by the same amount, about 23 percent, per 10 mg/dL lower ApoB, which makes ApoB a good single measure of the particles that build plaque.⁸ Reaching low levels may take a high-intensity statin, ezetimibe or a PCSK9 inhibitor: in FOURIER, evolocumab took LDL from a median of 92 to 30 mg/dL, and in the trial's long-term extension, with up to 8.4 years on the drug, side effects were no more common than with placebo.^9,10

Lp(a), the inherited wildcard. Large epidemiologic and genetic studies support a causal link between lipoprotein(a) and cardiovascular disease. The European Atherosclerosis Society recommends measuring it at least once in adulthood, and because no Lp(a)-lowering drug is yet available, it advises managing every other risk factor early and intensively when Lp(a) is high.¹¹

Triglycerides. Triglyceride-rich particles carry ApoB too, so they count toward risk (see above). Prescription omega-3s at 4 g a day lower very high triglycerides by 30 percent or more, and exercise and weight loss help as well.¹²

Testing and Monitoring for Cardiovascular Longevity

Coronary artery calcium (CAC) score — A low-dose CT scan that measures calcified plaque. In a comparison of six add-on risk markers in intermediate-risk adults followed for 7.6 years, coronary calcium had the strongest association with coronary events.¹³ A score of 0 means no calcified plaque was seen; it does not rule out soft plaque, so it doesn't cancel out other strong risk factors.

ApoB and LDL cholesterol — Recheck after any treatment change and then at least yearly, and watch the trend. Our Blood Panel Builder helps you put together a complete cardiovascular panel.

hs-CRP and inflammation — Inflammation contributes to plaque, but treating it is still unsettled. Low-dose colchicine reduced cardiovascular events after a recent heart attack in COLCOT (5.5 vs 7.1 percent) and in chronic coronary disease in LoDoCo2 (6.8 vs 9.6 percent), but in CLEAR SYNERGY, which started colchicine during treatment for an acute heart attack, it made no difference (hazard ratio 0.99).^14–16 Whether it suits you is a decision for your cardiologist.

Carotid intima-media thickness (CIMT) — An ultrasound measure of artery wall thickness. In the same six-marker comparison, CIMT was not associated with coronary events, so it adds little to standard risk assessment.¹³

Blood pressure — In SPRINT, adults at high cardiovascular risk without diabetes who targeted a systolic pressure below 120 mm Hg had 25 percent fewer major cardiovascular events and 27 percent lower mortality than those targeting below 140, at the cost of more episodes of low blood pressure, fainting and kidney injury.¹⁷ Use a validated home cuff to track the trend between visits.

Supplements and Medications with Cardiovascular Evidence

Statins remain the best-proven cardiovascular drug, for the reason given above: their benefit scales with how far LDL falls.⁷ Muscle symptoms are the main worry, but they are mostly not caused by the drug: in a meta-analysis of 19 blinded trials, statins caused about 11 extra reports of muscle pain or weakness per 1,000 people in the first year, so only about one in 15 such reports from statin users was actually due to the statin.¹⁸ Dose changes or switching agents often solve real intolerance.

Omega-3 fatty acids — In REDUCE-IT, 4 g a day of icosapent ethyl (purified EPA) cut major cardiovascular events by 25 percent in statin-treated people with high triglycerides.¹⁹ A 4 g EPA-plus-DHA product tested in STRENGTH was stopped early because benefit was unlikely.²⁰ Omega-3 supplements also raise the risk of atrial fibrillation, by 25 percent overall in a meta-analysis of outcome trials and by about 49 percent at doses above 1 g a day.²¹

Magnesium — In a meta-analysis of 34 placebo-controlled trials, a median 368 mg a day for three months lowered blood pressure by about 2 mm Hg systolic and 1.8 mm Hg diastolic.²² That is a small effect, most useful if your intake is low.

CoQ10 — In Q-SYMBIO, a randomized trial in chronic heart failure, the long-term rate of major cardiovascular events was 15 percent with CoQ10 versus 26 percent with placebo.²³ It was a single, modest-sized trial, so treat it as promising rather than settled, and don't use CoQ10 in place of standard heart failure treatment.

Vitamin K2 (MK-7) — The trial evidence is mixed. In AVADEC, two years of MK-7 plus vitamin D did not slow aortic valve calcification.²⁴ A 2026 trial in 180 people with coronary artery disease found that MK-7 slowed the rise in coronary calcium scores over two years, but no trial has yet shown fewer heart attacks or deaths.²⁵